Naba Alsaha posts 3% decline in 2021 net profit to SAR 25.8 mln
View other reports
Naba Alsaha Medical Services Co., which will list shares on Nomu-Parallel Market soon, reported a 3% decrease in 2021 net profit to SAR 25.8 million, from SAR 26.7 million a year earlier.
The lower profit was attributed to a 2.4% year-on-year (YoY) drop in operating income, as the cost of sales increased by 1.6% YoY. The company also cited higher general and administrative (G&A) expenses.
Financials (M)
| Item | 2020 | 2021 | Change |
|---|---|---|---|
| Revenues | 115.68 | 117.68 | 1.7 % |
| Gross Income | 45.93 | 46.78 | 1.9 % |
| Operating Income | 27.65 | 26.97 | (2.4 %) |
| Net Income | 26.65 | 25.83 | (3.1 %) |
| Average Shares | 10.50 | 10.50 | - |
| EPS (Riyals) | 2.54 | 2.46 | (3.1 %) |
The profit decline came despite a 1.7% YoY rise in revenue and lower financing costs.
Current Half Annual Comparison (M)
| Item | H2 2020 | H2 2021 | Change |
|---|
Shareholders’ equity stood at SAR 25.827 million by the end of 2021, down from SAR 26.653 million a year earlier.
The company’s cash balance grew to SAR 6.99 million in 2021, compared to SAR 1.79 million in 2020. Cash from operations came in at SAR 30.7 million, up from SAR 6 million in 2020.
Naba Alsaha is currently operating and managing Alzahra General Hospital, which posted annual revenue of SAR 109 million, compared to SAR 100 million in 2020. The company also manages and operates Manarat Al-Haramain Pharmacy, whose revenue fell to SAR 9 million in 2021, from SAR 15.5 million a year earlier.
No revenue was generated from Naba Alsaha’s maintenance services branch.
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| H1 2021 | 56.56 | - | 23.16 | - | 14.17 | - |
| H2 2021 | 61.12 | - | 23.63 | - | 12.80 | - |
| 2021 | 117.68 | 1.7 % | 46.78 | 1.9 % | 26.97 | (2.4 %) |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
|---|---|---|---|---|---|---|
| H1 2021 | 14.23 | - | 1.36 | - | 14.23 | 1.36 |
| H2 2021 | 11.60 | - | 1.10 | - | 11.60 | 1.10 |
| 2021 | 25.83 | (3.1 %) | 2.46 | - | 25.83 | 2.46 |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| H1 2021 | - | - | - |
| H2 2021 | 39.75 % | 28.12 % | 21.95 % |
| 2021 | 39.75 % | 28.12 % | 21.95 % |
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| H1 2021 | 10.50 | - | - | 8.82 |
| H2 2021 | 10.50 | 2.46 | 2.46 | 9.80 |
Multiple Ratios (End of Period Price)
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| H1 2021 | - | - | - |
| H2 2021 | - | - | - |
Business Segments (Million)
2021
| Period | Medical Services | Pharmaceuticals |
|---|
| Current | |
| Market Cap (M Riyal) | 850.50 |
| Enterprise Value (EV) (M) | 887.82 |
| Shares Outstanding ((M)) | 10.50 |
| Book Value (BV) ( Riyal) | 17.15 |
| Par Value ( Riyal) | 10.00 |
| Adjusted P/E (Last12) | 19.91 |
| Price/book | 4.72 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}